DK1853721T3 - Fremgangsmåde til bestemmelse af reaktionsevne over for CHK1-inhibitorer - Google Patents

Fremgangsmåde til bestemmelse af reaktionsevne over for CHK1-inhibitorer

Info

Publication number
DK1853721T3
DK1853721T3 DK06709785.7T DK06709785T DK1853721T3 DK 1853721 T3 DK1853721 T3 DK 1853721T3 DK 06709785 T DK06709785 T DK 06709785T DK 1853721 T3 DK1853721 T3 DK 1853721T3
Authority
DK
Denmark
Prior art keywords
chk1
patient
chk1 inhibitors
determining
determining reactivity
Prior art date
Application number
DK06709785.7T
Other languages
English (en)
Inventor
Sonya Zabludoff
Louise Bergeron
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1853721T3 publication Critical patent/DK1853721T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06709785.7T 2005-02-18 2006-02-16 Fremgangsmåde til bestemmelse af reaktionsevne over for CHK1-inhibitorer DK1853721T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65413105P 2005-02-18 2005-02-18
PCT/GB2006/000548 WO2006087557A1 (en) 2005-02-18 2006-02-16 METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS

Publications (1)

Publication Number Publication Date
DK1853721T3 true DK1853721T3 (da) 2010-06-14

Family

ID=36295309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06709785.7T DK1853721T3 (da) 2005-02-18 2006-02-16 Fremgangsmåde til bestemmelse af reaktionsevne over for CHK1-inhibitorer

Country Status (24)

Country Link
US (1) US20080145358A1 (da)
EP (1) EP1853721B1 (da)
JP (1) JP2008530575A (da)
KR (1) KR20070107034A (da)
CN (1) CN101120096A (da)
AT (1) ATE464395T1 (da)
AU (1) AU2006215413B2 (da)
BR (1) BRPI0607798A2 (da)
CA (1) CA2598185A1 (da)
CY (1) CY1110076T1 (da)
DE (1) DE602006013604D1 (da)
DK (1) DK1853721T3 (da)
ES (1) ES2341796T3 (da)
HK (1) HK1113059A1 (da)
HR (1) HRP20100313T1 (da)
IL (1) IL184873A0 (da)
MX (1) MX2007010073A (da)
NO (1) NO20074610L (da)
NZ (1) NZ556718A (da)
PL (1) PL1853721T3 (da)
PT (1) PT1853721E (da)
SI (1) SI1853721T1 (da)
WO (1) WO2006087557A1 (da)
ZA (1) ZA200706670B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005381A (es) * 2006-11-21 2009-06-30 Merial Ltd Vacuna para leishmania canina.
US8173366B2 (en) 2007-03-29 2012-05-08 University of Pittsburgh—of the Commonwealth System of Higher Education Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
WO2008121766A1 (en) 2007-03-29 2008-10-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Genetic changes in atm and atr/chek1 as prognostic indicators in cancer
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
JP5436786B2 (ja) * 2008-03-06 2014-03-05 オリンパス株式会社 細胞周期計測方法
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
WO2016126616A1 (en) 2015-02-02 2016-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax
KR20180126085A (ko) * 2016-05-05 2018-11-26 난토믹스, 엘엘씨 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor)
EP3499228A4 (en) * 2016-08-12 2020-04-15 Hitachi Chemical Company, Ltd. METHOD FOR DETECTING CIRCULATING TUMOR CELLS AND PRE-TREATMENT METHOD FOR DETECTING CIRCULATING TUMOR CELLS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001161398A (ja) * 1999-12-06 2001-06-19 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素の活性測定方法およびタンパク質リン酸化酵素の活性測定キット
EP1947102A1 (en) * 2003-01-09 2008-07-23 Pfizer, Inc. Compositions comprising diazepinoindole derivatives as kinase inhibitors
BRPI0408256A (pt) * 2003-03-14 2006-03-01 Astrazeneca Ab composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
EP1620544B1 (en) * 2003-04-17 2018-09-19 Alnylam Pharmaceuticals Inc. MODIFIED iRNA AGENTS
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20050207998A1 (en) * 2003-07-21 2005-09-22 Yaoping Lu Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
JP2007519609A (ja) * 2003-09-17 2007-07-19 アイコス コーポレイション 細胞増殖を制御するためのｃｈｋ１インヒビターの使用

Also Published As

Publication number Publication date
CY1110076T1 (el) 2015-01-14
SI1853721T1 (sl) 2010-06-30
CN101120096A (zh) 2008-02-06
DE602006013604D1 (de) 2010-05-27
AU2006215413B2 (en) 2010-10-07
CA2598185A1 (en) 2006-08-24
BRPI0607798A2 (pt) 2010-06-22
ES2341796T3 (es) 2010-06-28
NZ556718A (en) 2010-10-29
HK1113059A1 (en) 2008-09-19
KR20070107034A (ko) 2007-11-06
JP2008530575A (ja) 2008-08-07
IL184873A0 (en) 2007-12-03
US20080145358A1 (en) 2008-06-19
AU2006215413A1 (en) 2006-08-24
PT1853721E (pt) 2010-06-08
WO2006087557A1 (en) 2006-08-24
ATE464395T1 (de) 2010-04-15
EP1853721B1 (en) 2010-04-14
NO20074610L (no) 2007-11-14
ZA200706670B (en) 2008-10-29
EP1853721A1 (en) 2007-11-14
PL1853721T3 (pl) 2010-08-31
MX2007010073A (es) 2007-10-10
HRP20100313T1 (hr) 2010-07-31

Similar Documents

Publication Publication Date Title
DK1853721T3 (da) Fremgangsmåde til bestemmelse af reaktionsevne over for CHK1-inhibitorer
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
BRPI0515758A (pt) dispositivo de ensaio de diagnóstico
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
FR2855877B1 (fr) Determination precoce des resultats de tests
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
NZ597628A (en) Hla-b5801 allele associated with adverse drug reactions and methods for detecting such
WO2008030892A3 (en) Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
WO2008054827A3 (en) Bruton's tyrosine kinase activity probe and method of using
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
DE602006016589D1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
WO2009015233A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
NO20070521L (no) Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40
WO2007114986A3 (en) Cooperative probes and methods of using them
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
EA201000734A1 (ru) Способ и аппарат для мониторинга пространственного образования фибринового сгустка
DE602007001103D1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
DK1692102T3 (da) Sammensætninger og fremgangsmåder til at påvise og behandle sygdomme og tilstande knyttet til chemokinreceptorer
DE602007013080D1 (de) Isotopenmarkiertes einfangmittel und verfahren zur identifizierung reaktiver metaboliten
DE602007010246D1 (de) Verfahren zur blutgerinnungsbestimmung